BCIQ Profiles

Company Profile Report
1006 ECP Scribe EMBARGO 7AM PT TUES
BioCentury & Getty Images

Emerging Company Profile

Scribe: engineering CRISPR’s next generation

Doudna’s latest CRISPR play uses engineered enzymes to improve therapeutic properties

Doudna’s latest CRISPR play uses engineered enzymes to improve therapeutic properties.

Oct 6, 2020 | 10:26 PM GMT

Scribe is carving out a new space in the gene editing landscape with a next-generation version of the technology from Jennifer Doudna’s lab that substitutes engineered CRISPR enzymes for their natural counterparts.

Scribe Therapeutics

Read the full 762 word article

How to gain access

Continue reading with a
two-week free trial.